Clinical Trial: Extended Open Challenge in Patients With a History of Drug Eruption Following Beta-lactam Treatment
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title:
Brief Summary: Beta-lactam allergy is the most prevalent drug allergy. Drug eruption is the most common symptom whereas life-threatening anaphylaxis is rather rare. A recently published study (Journal of Allergy and Clinical Immunology, January 2011, Vol. 127, p. 218-222) described the safety of a 2-day oral beta-lactam challenge in penicillin-allergic patients, disregarding their penicillin skin test results. In the proposed study the investigators will similarly challenge beta-lactam allergic patients, both children and adults for an extended (5 days) period of time. The study will include patients with a history of a skin rash following beta-lactam administration as well as patients who cannot provide any data on their presumed allergic reaction, disregarding their penicillin skin test results.
Detailed Summary:
Sponsor: Meir Medical Center
Current Primary Outcome: The safety of a 5-day oral challenge in patients with suspected beta-lactam allergy [ Time Frame: 5 days ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Meir Medical Center
Dates:
Date Received: November 20, 2011
Date Started: March 2012
Date Completion:
Last Updated: October 6, 2015
Last Verified: October 2015